Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \>= 18 years old~* Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic) and determined to be BRAF V600E or V600K mutation-positive (cohort A) or mutation-negative (cohorts B and C)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Measurable disease by radiographic or physical examination~* Adequate organ and marrow function~* Willingness to provide consent for biopsies positive or BRAF WT measurable disease and adequate organ and marrow function~Exclusion Criteria:~* Prior treatment with a BRAF inhibitor or MEK inhibitor~* Any prior Grade \>= 3 immune-related adverse event while receiving immunotherapy~* Active or prior documented autoimmune disease within the past 2 years~* History of or current risk for retinal vein occlusion (RVO) or central serous retinopathy (CSR)~* History of or current cardiovascular risk including myocardial infarction, \>= Class II congestive heart failure, uncontrolled arrhythmias, or refractory hypertension~* Active, untreated central nervous system (CNS) metastases~* Women who are pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A1: Durvalumab (3 mg/kg) + Dabrafenib +Trametinib (Type: EXPERIMENTAL): Participants will receive intravenous (IV) dose of 3 milligrams per kilogram (mg/kg) durvalumab every 2 weeks (Q2W) from Day 1 up to 12 months along with oral 150 mg dabrafenib capsule twice daily (BID) and oral 2 mg trametinib tablet once daily (QD) until confirmed disease progression (PD), initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 3 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
- Cohort A2: Durvalumab (10 mg/kg) + Dabrafenib +Trametinib (Type: EXPERIMENTAL): Participants will receive IV dose of 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral doses of dabrafenib 150 mg capsule BID and trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
- Cohort B: Durvalumab (10 mg/kg) +Trametinib (Concurrent) (Type: EXPERIMENTAL): Participants will receive concurrent doses of IV 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral dose of trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of trametinib.
- Cohort C: Durvalumab (10 mg/kg) +Trametinib (Sequential) (Type: EXPERIMENTAL): Participants will receive sequential doses of oral trametinib tablet 2 mg QD from Day 1 to Day 42 and IV durvalumab 10 mg/kg Q2W starting from Day 29 (Week 5) up to 12 months. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).